Bli medlem
Bli medlem

Du är här

2016-09-07

Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Apricus Biosciences, Inc.
Press release

Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global
Investment Conference

SAN DIEGO, 2016-09-07 13:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing
innovative medicines in urology and rheumatology, today announced that Richard
Pascoe, Chief Executive Officer, will present at the Rodman & Renshaw 18th
Annual Global Investment Conference on Tuesday, September 13, 2016, at 3:25
p.m. Eastern Time. The conference will be held at The Lotte New York Palace
Hotel in New York, NY. Mr. Pascoe will provide an update on the Company’s
strategy and development plans surrounding Vitaros®.

A live audio webcast of the presentation can be accessed via the Investor
Relations’ section of the Company's website at www.apricusbio.com. Please log
in approximately 5-10 minutes before the event to ensure a timely connection. A
replay of the webcast will be available for 30 days following the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus’ commercial product,
Vitaros®, for the treatment of erectile dysfunction, is approved in Europe,
part of the Middle East, and Canada, and is being commercialized in several
countries in Europe. In September 2015, Apricus in-licensed the U.S.
development and commercialization rights for Vitaros from Allergan. Apricus’
marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati
S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals),
Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd.
Apricus currently has one active product candidate, RayVa™, its product
candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.

For further information on Apricus, visit http://www.apricusbio.com.

*Vitaros® is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.

CONTACT:
Institutional / Retail Investors: Matthew Beck
mbeck@troutgroup.com
The Trout Group LLC
(646) 378-2933

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.